At the same time, in the inflammatory environment, platelets with PD-L1 antibodies modified on the surface can be activated and release anti-PD-L1 antibodies, block the inhibition pathway of the immune checkpoint, enhance the killing capacity of CAR-T cells, and more effectively inhibit the recurrence of cancer after surgery. Here, CD274 is linked to cancer.